GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

AZD0233   Click here for help

GtoPdb Ligand ID: 14193

Synonyms: AZD-0233 | example 46 (isomer 2) [WO2024083933]
Compound class: Synthetic organic
Comment: The chemical structure for AZD0233 was disclosed during the First Time Disclosures session at the ACS Fall 2025 meeting. It was disclosed as a chemokine CX3CR1 antagonist. It is one of the compounds claimed in patent WO2024083933A1 [1]. It is proposed to work via antagonism of CX3CR1/CX3CL1(fractalkine) signaling, as soluble fractalkine elevation has been associated with heart failure in preclinical models and in humans.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 145.48
Molecular weight 456.54
XLogP 0.28
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)C[C@H](CO)NC1=NC(=NC(=N1)NS(=O)(=O)C)C[C@@H](C)C2=C(C=C(N=C2)OC)F
Isomeric SMILES COC1=NC=C([C@H](C)CC2=NC(N[C@@H](CO)CC(C)C)=NC(NS(C)(=O)=O)=N2)C(F)=C1
InChI InChI=1S/C19H29FN6O4S/c1-11(2)6-13(10-27)22-18-23-16(24-19(25-18)26-31(5,28)29)7-12(3)14-9-21-17(30-4)8-15(14)20/h8-9,11-13,27H,6-7,10H2,1-5H3,(H2,22,23,24,25,26)/t12-,13-/m1/s1
InChI Key BJHGVSXKHJAFFX-CHWSQXEVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Nilsson K, Bauer M, Olwegard-Halversson M, Brink M, Janet JP. (2024)
2,4,6-trisubstituted 1,3,5-triazines as modulators of cx3cr1.
Patent number: WO2024083933A1. Assignee: Astrazeneca Ab. Priority date: 18/10/2023. Publication date: 25/04/2024.